Cholesterol and lipid medicines

Hypolipidaemic agents

Find reliable independent health and treatment information about the cholesterol and lipid medicines subcategory of medicines. This includes resources for consumers and health professionals.

The Cholesterol and lipid medicines subcategory of medicines is also known as anticholesteraemic agents, dyslipidaemia, medicines for, lipid-lowering medicines, lipid-modifying medicines and hypolipidaemic agents.

You can also search for an active ingredient, brand or other category of medicine using our Medicine Finder.

Latest information - cholesterol and lipid medicines

Audience:
       

Content type:

Sitagliptin with simvastatin (Juvicor) for type 2 diabetes and high…
(Consumer publication)
04 Apr 2013 – Find out all about sitagliptin with simvastatin (brand name Juvicor), a new combination medicine for people with type 2 diabetes and high cholesterol.
Glucose-lowering drugs information
For health professionals (Health professional publication)
01 Aug 2012 – Table of advantages and disadvantages of glucose-lowering drugs and PBS listings
Type 2 diabetes
For health professionals (Health professional publication)
01 Aug 2012 – Focuses on the role of drug treatments to reduce cardiovascular risk in type 2 diabetes, requires management of lifestyle, BP, lipids and glucose.
Statins remain important for people at high risk of heart attack or…
(Media release)
01 Mar 2012 – NPS is urging people taking statins to continue to take their medicine as prescribed and to see their doctor if they are unsure about the benefit of the medicine for them.
Are cholesterol medicines overused?
(Media release)
01 Dec 2011 – Medicines to treat cholesterol may be being prescribed inappropriately, according to Associate Professor Jane Smith of Bond University. Heart disease is a common problem, causing 16% of the total disease burden in Australia - second only to cancer. However treatment with statins should be focused on those at high risk
Evidence for using Co-enzyme Q10 with statins
(Medicine)
30 Sep 2011 – Evidence does not support the use of Co-enzyme Q10 to prevent myalgia (muscle pain) during treatment with a statin. Evidence does not support use of vitamin D3 to prevent myalgia (muscle pain) during treatment with a statin, or for the sole purpose of improving cardiovascular health.
An easy way to review patients at risk of cardiovascular disease
(Media release)
16 Aug 2011 – The latest Clinical e-Audit from NPS allows GPs and GP registrars to quickly and easily target lipid-modifying therapy to those patients at increased cardiovascular disease (CVD) risk as part of a quality improvement cycle
Daily dose requirements removed from PBS listings for ezetimibe and…
For health professionals (Health professional publication)
01 Jul 2011 – Daily dose requirements removed from the PBS listings for ezetimibe and ezetimibe with simvastatin (Ezetrol, Vytorin).
Pharmacy Practice Review — reducing cardiovascular disease risk
(Media release)
07 Jun 2011 – Pharmacy Practice Review — Reducing cardiovascular disease (CVD) risk is part of the 2011 NPS therapeutic program on CVD risk and guiding lipid management for health professionals and builds on the NPS vision to encourage quality use of medicines
Find out your risk score before it's game over
(Media release)
11 Apr 2011 – Australians should pay as much attention to their heart and stroke risk score as the footy score this autumn, according to NPS MedicineWise, which has launched a new campaign focusing on cardiovascular disease
View more

Active ingredients used in cholesterol and lipid medicines